Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 4
2006 1
2007 5
2008 5
2009 3
2010 4
2011 9
2012 12
2013 14
2014 11
2015 9
2016 8
2017 12
2018 6
2019 7
2020 10
2021 4
2022 4
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Wei F, et al. Among authors: sasada t. J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788. J Immunother Cancer. 2023. PMID: 37433717 Free PMC article.
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: sasada t. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: sasada t. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Exhaustion of CAR T cells: potential causes and solutions.
Kouro T, Himuro H, Sasada T. Kouro T, et al. Among authors: sasada t. J Transl Med. 2022 May 23;20(1):239. doi: 10.1186/s12967-022-03442-3. J Transl Med. 2022. PMID: 35606821 Free PMC article. Review.
Next-generation peptide vaccines for advanced cancer.
Yamada A, Sasada T, Noguchi M, Itoh K. Yamada A, et al. Among authors: sasada t. Cancer Sci. 2013 Jan;104(1):15-21. doi: 10.1111/cas.12050. Epub 2012 Dec 4. Cancer Sci. 2013. PMID: 23107418 Free PMC article. Review.
Prospects for a personalized peptide vaccine against lung cancer.
Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T. Nakahara Y, et al. Among authors: sasada t. Expert Rev Vaccines. 2019 Jul;18(7):703-709. doi: 10.1080/14760584.2019.1635461. Epub 2019 Jun 28. Expert Rev Vaccines. 2019. PMID: 31225971 Review.
131 results